Project Grant R01AG083423

STATISTICAL METHODS TO CHARACTERIZE PATIENTS WHO HIGHLY BENEFIT ACROSS MULTIFACETED CLINICAL OUTCOMES, FROM TREATMENTS IN ALZHEIMERS DISEASE AND RELATED DEMENTIAS (ADRD) - PROJECT SUMMARY METHODS TO CHARACTERIZE PATIENTS WHO HIGHLY BENEFIT ON MULTIPLE CLINICAL OUTCOMES, FROM TREATMENTS IN ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (ADRD), ARE NECESSARY TO TREAT PATIENTS EFFECTIVELY. TREATMENTS MAY BENEFIT SOME PATIENTS ON TARGETED OUTCOMES, BUT HARM SOME PATIENTS ON OTHER, E.G., COGNITIVE, OUTCOMES. SO, CHARACTERIZING PATIENTS WHO HIGHLY BENEFIT ON MULTIPLE OUTCOMES IS SIGNIFICANT: FIRST IT ALLOWS THESE PATIENTS TO CHOOSE A TREATMENT IF IT IS PREDICTED TO GIVE THEM HIGH BENEFITS WITHOUT THE HARMS; SECOND, ACCURATE CHARACTERIZATION METHODS DO NOT EXIST. GENERALLY, A CHARACTERIZATION METHOD HAS TWO STAGES. ONE STAGE "CONSTRUCTS" OUTCOME PREDICTIONS BASED ON PATIENTS' COVARIATES; AND ANOTHER STAGE "SYNTHESIZES" THE PREDICTIONS TO ESTIMATE THE GOAL - A LARGE HIGH BENEFIT GROUP. AS THE "CONSTRUCTION" STAGE USES MANY COVARIATES, IT NEEDS METHODS TO ESTIMATE PREDICTIONS FROM A MODEL, I.E., FROM A LARGE SET OF POSSIBLE DISTRIBUTIONS (E.G., REGRESSION, NEURAL NETWORKS). THESE PREDICTIONS ARE THEN USED IN THE "SYNTHESIS" STAGE FOR THE GOAL. SUCH EXISTING METHODS, HOWEVER, DO NOT USE THE CLINICAL GOAL (TO CHARACTERIZE HIGH-BENEFIT PATIENTS) AS A GUIDE INSIDE THE CONSTRUCTION STAGE. FOR A SINGLE OUTCOME, RECENT WORK HAS SHOWN THAT THIS LACK OF LINKING CAN PRODUCE DRAMATICALLY INACCURATE CHARACTERIZATIONS, NO MATTER THE MODEL. FOR CHARACTERIZING PATIENTS WITH MULTIPLE HIGH BENEFITS, NEW METHODS MUST EXPLICITLY LINK ALL MULTIPLE CLINICAL GOALS (I.E. HIGH BENEFITS IN ALL OUTCOMES) IN THE CONSTRUCTION STAGE. IN PREPARATORY WORK, WE SHOWED THAT EXISTING METHODS FOR MULTIPLE OUTCOMES, CAN MISS EVEN MOST OF THE HIGH BENEFIT PATIENTS, AND WE DEVELOPED A PRELIMINARY BETTER METHOD BY ESTABLISHING THE MISSING LINKS. THIS NEW PROJECT IS MOTIVATED BY OUR ONGOING WORK WITH TWO STUDIES. THE FIRST STUDY TESTED IF CITALOPRAM REDUCES AGITATION IN ALZHEIMER'S PATIENTS. SINCE CITALOPRAM MAY HARM COGNITIVE FUNCTION, WE SET TO CHARACTERIZE PATIENTS WITH HIGH CITALOPRAM EFFECT IN (A) REDUCING AGITATION AND (B) MAINTAINING COGNITIVE FUNCTION. THE SECOND STUDY TESTS THE EFFECT OF TRANSCRANIAL DIRECT CURRENT STIMULATION ON PRIMARY PROGRESSIVE APHASIA OUTCOMES, WITH RELATED GOALS. IN PREPARATORY WORK, WE FOUND STRONG EVIDENCE THAT STANDARD METHODS MISS UP TO 70% OF THE PATIENTS WITH MULTIPLE HIGH BENEFITS, COMPARED TO THE NEW METHODS. FOR THIS PROJECT WE PROPOSE TO FULLY DEVELOP METHODS TO CHARACTERIZE PATIENTS WHO HIGHLY BENEFIT ON MULTIPLE OUTCOMES. THE METHODS WILL BE APPLIED TO THE ABOVE STUDIES, AND CAN HELP MORE GENERALLY IN OTHER ADRD STUDIES. AIM 1. DEVELOP METHODS TO CHARACTERIZE PATIENTS WHO HIGHLY-BENEFIT IN MULTIPLE OUTCOMES IN RANDOMIZED TRIALS. THESE METHODS ARE SIGNIFICANT BECAUSE THEY ALLOW ACCURATE PERSONALIZED TREATMENT CHOICES. AIM 2. DEVELOP METHODS TO FIND IF A SIMPLER SUBSET OF THE FULL MULTIPLE OUTCOMES, CAN HAVE SIMILAR PATIENT CHARACTERIZATION AS THE FULL OUTCOMES. THESE METHODS ARE SIGNIFICANT BECAUSE THEY CAN SUGGEST IF A HIGH-EFFECT ON EARLIER OUTCOMES IS NECESSARY BEFORE A HIGH-EFFECT ON THE LATER OUTCOMES OCCURS. AIM 3. DEVELOP METHODS TO CHARACTERIZE PATIENTS WHO HIGHLY BENEFIT IN MULTIPLE OUTCOMES IN OBSERVATIONAL STUDIES. THESE METHODS ARE SIGNIFICANT WHEN RANDOMIZATION IS INFEASIBLE.